Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Inclusion Criteria:

   - Newly diagnosed acute lymphoblastic leukemia (ALL)

      - Definitive evidence of BCR-ABL fusion (Philadelphia chromosome positive [PH+])
      from an approved Children's Oncology Group (COG) cytogenetics laboratory

   - Meets one of the following criteria:

      - Concurrent enrollment on Clusters of Orthologous Groups (COG)-AALL03B1 (or a
      successor trial) AND COG-AALL0232, COG-AALL0331, COG-AALL0434 or other front-line
      COG ALL clinical trial

      - Concurrent enrollment on COG-AALL03B1 (or a successor trial) AND scheduled to
      receive a 3 or 4-drug standard induction regimen

      - Concurrent enrollment on a Dana-Farber Cancer Institute (DFCI) Childhood ALL
      Consortium trial (or scheduled to be treated as per a DFCI Childhood ALL
      Consortium induction regimen)

   - All patients must have definitive evidence of BCR-ABL fusion from an approved COG
   cytogenetics laboratory; patients may NOT have received Day 15 of Induction
   chemotherapy (or day 18 vincristine if enrolled on a DFCI Childhood ALL Consortium
   trial) prior to enrollment on AALL0622

   - Patients must have a performance status of 0, 1 or 2 at completion of two weeks of
   Induction; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16
   years of age

   - Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70mL/min/1.73
   m^2 or maximum serum creatinine based on age and gender as follows:

      - 0.4 mg/dL (for patients 1 to 5 months of age)

      - 0.5 mg/dL (for patients 6 to 11 months of age)

      - 0.6 mg/dL (for patients 1 year of age)

      - 0.8 mg/dL (for patients 2 to 5 years of age)

      - 1.0 mg/dL (for patients 6 to 9 years of age)

      - 1.2 mg/dL (for patients 10 to 12 years of age)

      - 1.5 mg/dL (males) or 1.4 mg/dL (females) (for patients 13 to 15 years of age)

      - 1.7 mg/dL (males) or 1.4 mg/dL (females) (for patients >= 16 years of age)

   - Total bilirubin =< 1.5 times upper limit of normal (ULN) for age

   - Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 2.5
   times ULN for age

   - Shortening fraction >= 27% by echocardiogram or ejection fraction >= 50% by gated
   radionuclide study

   - No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% at
   sea level if there is clinical indication for determination

   - Patients with seizure disorder may be enrolled if on anticonvulsants and well
   controlled; however, drugs that induce CYP3A4/5 (carbamazepine, oxcarbazepine,
   phenytoin, primidone, phenobarbital) should be avoided

   - Patients will start AALL0622 therapy on day 15 of induction therapy (or day 18 if
   enrolled on a DFCI Childhood ALL Consortium trial); patients must have received the
   first 2 weeks of Induction therapy

Exclusion Criteria:

   - Females of childbearing potential must have a negative pregnancy test; patients of
   childbearing potential must agree to use an effective birth control method

   - Female patients who are lactating must agree to stop breast-feeding

   - Patients with Down syndrome

   - Patients with any clinically significant cardiovascular disease including the
   following:

      - Myocardial infarction or ventricular tachyarrhythmia within 6 months

      - Ejection fraction less than institutional normal

      - Major conduction abnormality (unless a cardiac pacemaker is present)